FAQ: NanoViricides Presentation at PODD 2025 Conference and Antiviral Pipeline Updates
Summary
NanoViricides will present updates on its antiviral drug pipeline and platform technologies at the PODD 2025 Conference, with lead candidate NV-387 advancing toward Phase II trials for MPox and respiratory viral infections after showing strong preclinical efficacy against multiple viruses.
What is the main announcement in this content?
NanoViricides will present at the PODD 2025 Conference on October 27, 2025, where President and Executive Chairman Anil R. Diwan, PhD will provide updates on the company’s antiviral drug pipeline and platform technologies available for licensing.
Where and when is the PODD 2025 Conference taking place?
The conference will be held on Monday, October 27, 2025, at 3 p.m. ET in Track 5A at the Westin Copley Hotel in Boston.
What is NanoViricides’ lead drug candidate and what conditions is it targeting?
The lead candidate is NV-387, a broad-spectrum antiviral drug advancing toward Phase II trials for MPox and respiratory viral infections, with plans to develop it as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections.
What preclinical results have been shown for NV-387?
Preclinical studies have shown strong efficacy against RSV, Influenza A, and Coronaviruses.
What other advanced drug candidate does NanoViricides have in development?
The company has NV-HHV-1 for the treatment of Shingles as another advanced drug candidate.
What is NanoViricides’ business model and technology foundation?
The company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, using the nanoviricide platform technology that creates special purpose nanomaterials for antiviral therapy.
What viral diseases is NanoViricides developing drugs against?
The company is developing drugs against numerous viral diseases including oral and genital Herpes, viral eye diseases, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.
What licenses does NanoViricides hold for its technology?
The company holds worldwide exclusive perpetual licenses for several drugs targeting specific human viral diseases including HIV/AIDS, Hepatitis B and C, Rabies, Herpes, Influenza, Dengue, Ebola/Marburg viruses, and certain Coronaviruses.
What are the next steps for NanoViricides’ drug development?
The company is currently focused on advancing NV-387 into Phase II human clinical trials, though it cannot project exact dates for IND filings due to dependence on external collaborators and consultants.
Where can I find more detailed information about this announcement?
The full press release can be viewed at https://ibn.fm/Z4d0g, and additional company information is available at www.nanoviricides.com.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 265878